Emergent BioSolutions Reports $110M Revenue, $0.64 Loss Per Share
For the 2026 quarter, Emergent BioSolutions reported a $32.7 million net loss, compared with net income of $51.2 million in the prior-year quarter. Revenue was $110 million versus $231.1 million, and diluted loss per share was $0.64 versus earnings per share of $0.91.
Emergent BioSolutions reported revenue of $110M and a net loss of $32.7M for the 2026 quarter, compared with revenue of $231.1M and net income of $51.2M in the prior-year quarter. Diluted loss per share was $0.64, versus earnings per share of $0.91.Financial Highlights¹ Reported as “Total revenues”…